Search Results - "Orman JS"

Emerging pharmacological strategies supporting symptom management in borderline personality disorder: current evidence and future directions.

Authors: Pałuchowski, Michał Krawczyk, Anna Mozer, Maciej et al.

Source: Psychiatry / Psychiatria. 2025, Vol. 22, p22-31. 10p.

Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.

Authors: Klaire, Sukhpreet Zivanovic, Rebecca Barbic, Skye Pamela et al.

Source: American Journal on Addictions. Jul2019, Vol. 28 Issue 4, p262-265.

Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program.

Authors: Furo, Hiroko Schwartz, Diane G Sullivan, Ross W et al.

Source: Substance Abuse: Research & Treatment. 12/6/2021, p1-9. 9p.

Identifying facilitators and barriers to the uptake of medication for opioid use disorder in Washington, DC: A community-engaged concept mapping approach.

Authors: Gullahorn, Britta Kuo, Irene Robinson, Artius M. et al.

Source: PLoS ONE. 7/19/2024, Vol. 19 Issue 7, p1-18. 18p.

Association Between Buprenorphine Dose and the Urine "Norbuprenorphine" to "Creatinine" Ratio: Revised.

Authors: Furo, Hiroko Wiegand, Timothy Rani, Meenakshi et al.

Source: Substance Abuse: Research & Treatment. 3/13/2023, p1-11. 11p.

Current awareness in human psychopharmacology.

Source: Human Psychopharmacology: Clinical & Experimental. Jan2010, Vol. 25 Issue 1, pi-viii. 8p.

Subjects: Bibliography, Publishing, Psychopharmacology, Psychiatric drugs, Antidepressants, Neuropeptides

Spotlight on buprenorphine/naloxone in the treatment of opioid dependence.

Authors: Orman JS Keating GM Orman, Jennifer S et al.

Source: CNS Drugs. 2009, Vol. 23 Issue 10, p899-902.

Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.

Authors: Orman JS Keating GM

Source: Drugs. 2009, Vol. 69 Issue 5, p577-607.

URL: 43935713

Tipranavir: a review of its use in the management of HIV infection.

Authors: Orman JS Perry CM

Source: Drugs. 2008, Vol. 68 Issue 10, p1435-1463.

URL: 33208872

Trastuzumab: In HER2 and Hormone Receptor Co-Positive Metastatic Breast Cancer.

Authors: Orman JS Perry CM

Source: Drugs. 2007, Vol. 67 Issue 18, p2781-2789.

URL: 28600972

Retrospective analysis of heroin detoxification with buprenorphine in a psychiatric hospital in Japan.

Authors: Nagano, Tatsushi Kimoto, Sohei Aso, Katsuro et al.

Source: Neuropsychopharmacology Reports. Dec2020, Vol. 40 Issue 4, p376-382. 7p.

Buprenorphine is a weak dopamine releaser relative to heroin, but its pretreatment attenuates heroin‐evoked dopamine release in rats.

Authors: Isaacs, Dominic P. Leman, Ryan P. Everett, Thomas J. et al.

Source: Neuropsychopharmacology Reports. Dec2020, Vol. 40 Issue 4, p355-364. 10p.

Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: Results from a 12-month observational study.

Authors: Soyka, Michael Backmund, Markus Schmidt, Peggy et al.

Source: American Journal on Addictions. Nov2014, Vol. 23 Issue 6, p563-569.

After the randomised injectable opiate treatment trial: Post-trial investigation of slow-release oral morphine as an alternative opiate maintenance medication.

Authors: BOND, ALYSON J. REED, KYLIE D. BEAVAN, PETE et al.

Source: Drug & Alcohol Review. Jun2012, Vol. 31 Issue 4, p492-498.

QSAR study of human epidermal growth factor receptor (EGFR) inhibitors: conformation-independent models.

Authors: Fioressi, Silvina E. Bacelo, Daniel E. Duchowicz, Pablo R.

Source: Medicinal Chemistry Research. Nov2019, Vol. 28 Issue 11, p2079-2087. 9p.

Low-dose Initiation of Buprenorphine in Hospitalized Patients on Full Agonist Opioid Therapy: A Retrospective Observational Study.

Authors: Schult RF Maynard KM Corvelli JM et al.

Source: Journal of addiction medicine [J Addict Med] 2023 Nov-Dec 01; Vol. 17 (6), pp. 685-690. Date of Electronic Publication: 2023 Aug 18.

Publication Type: Observational Study; Journal Article

Journal Info: Publisher: Wolters Kluwer Health, Inc Country of Publication: Netherlands NLM ID: 101306759 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1935-3227 (Electronic) Linking ISSN: 19320620 NLM ISO Abbreviation: J Addict Med Subsets: MEDLINE

Assessment of the effects of contingent histamine injections on the reinforcing effectiveness of cocaine using behavioral economic and progressive-ratio designs.

Authors: Freeman, Kevin McMaster, Brian Roma, Peter et al.

Source: Psychopharmacology. Jun2014, Vol. 231 Issue 12, p2395-2403.

The challenge of perioperative pain management in opioid-tolerant patients.

Authors: Coluzzi, Flaminia Bifulco, Francesca Cuomo, Arturo et al.

Source: Therapeutics & Clinical Risk Management. Sep2017, Vol. 13, p1163-1173. 11p.

Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center.

Authors: Toce, Michael S. Burns, Michele M. O'Donnell, Katherine A.

Source: Clinical Toxicology (15563650). Jan2017, Vol. 55 Issue 1, p12-17. 6p.

Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening.

Authors: Zheng Shi Tian Yu Rong Sun et al.

Source: Pharmacognosy Magazine. Apr-Jun2016, Vol. 12 Issue 46, p139-144. 6p.